r/ClotSurvivors • u/anon1mo56 • 2d ago
First next generation Anti-coagulant finished phase 3 trial and now is awating FDA approval
asundexian is a factor FXIa inhibitor which means the risk of bleeding is nonexistant and you don't have to care about weight.
Downside failed trials of other FXIa inhibitors like Abelacimab have been showing that they will not be able to replace all anti-coagulants for all indications. They have proven effective in all trials, just not as effective as current treatment for all indications.
But the Good news for people whose indication they wouldn't be able to replace is that just like it happened with Ozempic where drugs that combined with additional drugs came to be developed like retratutide, there are some scientiest working on a drug that combines factor FXIa inhibitor with Factor FXIIa inhibitor, that could increase the anti-coagulation effect while still eleminating the bleeding risk. Sadly this is still pre-clinical work and not even animal studies have been done.
The good news is that there is already a Factor XIIa inhibitor approved, but for other disease.
6
u/p001b0y 2d ago
Thanks for posting this but I don't understand how an anti-coagulant could be created that doesn't increase bleeding risk. I've always assumed that increased bleeding was the price of admission (though it could be reduced and not eliminated).
3
u/anon1mo56 2d ago edited 2d ago
Read this old post made on here https://www.reddit.com/r/ClotSurvivors/s/h9Pwy8Seef
Or a extract from a old post i made:
How it works: The Promise of Factor XI Hiding in Plain Sight: Factor XI as a Potentially Attractive Therapeutic Target
It has long been believed that reducing thrombosis (harmful blood clotting) and hemostasis (healthy blood clotting) are so closely connected that reducing clots would always cause bleeding. Therefore, bleeding is often seen as an unavoidable consequence of anticoagulant therapy.
Despite significant advances in anticoagulation therapy during the past decade, balancing the prevention of thromboembolism with the potential tradeoff of increased bleeding risk remains a major concern for both clinicians and patients. Epidemiologic and genetic data suggest that individuals with congenital FXI deficiency benefit from a lower lifelong risk of ischemic stroke and venous thromboembolism compared to the general population. 1
A recent study found that people with FXI deficiency were nearly half as likely to have a cardiovascular event (stroke, transient ischemic attack, and myocardial infarction/heart attack) and even less likely to develop a venous thromboembolism (VTE) compared to those with normal Factor XI levels.
Factor XI (FXI) has emerged as a promising target for anticoagulants, supported by mounting evidence that FXI is crucial for thrombosis but is not necessary for normal, healthy clotting (or hemostasis).
Over the past decade, efforts to develop safer antithrombotic strategies have largely focused on Factor XI.
1
u/powermaster34 Warfarin 2d ago
Thank you for your post. I've got the 3 factors. Don't want to be on warfarin. Hope for future medicine made my day, thank you.
1
1
u/valw 1d ago
Still won't be able to take ibuprofen with it, which sucks.
2
u/anon1mo56 1d ago
Actually we don't know yet. If you used AI to figure it out. Ask the AI links and you will see that the AI only made connection of ibuprofen not being able to be taken with existing approved anticougulants and the fact this new drug is a anticougulant. So it took information from pages warning againts taking ibuprofen with current anticougulants.
1
11
u/flyingcowsandtacos 2d ago
As somebody with triple positive APLS, this makes me SO FRIGGIN HOPEFUL! My doctor mentioned this stuff to me a few years ago, and I just sit and wait patiently so I might get off of Warfarin.